Effects of topical administration of beclomethazone dipropionate on the symptoms of chronic rhinitis

The aim of this study was to evaluate the effect of topical administration of corticosteroid beclomethasone dipropionate on common nasal symptoms in moderate allergic and non-allergic hyperreactive eosinophilic rhinitis, and in allergic and non-allergic hyperreactive eosinophilic rhinitis associated with bilateral moderate nasal polyposis. The study was prospective and controlled. During the study 106 patients were examined, out of whom 66 were treated, while 40 had no therapy. Beclomethasone diproprionate nasal spray was administered in the daily dose of 400 ?g. Patients with isolated rhinitis underwent 3 otorhinolaryngologic examinations during the six-week treatment. Patients with nasal polyposis underwent 4 otorhinolaryngologic examinations during six-month treatment. One-week therapy showed highly significant decrease of the average score of symptoms of isolated rhinitis in relation to basal condition. No further significant change was noted after six-week therapy. Six-week therapy of nasal polyposis exerted significantly reduced score of symptoms in relation to basic condition. During further treatment no significant reduction of symptoms was noted. Follow-up period of all control subgroups showed no significant change of symptom scores. Topical therapy with beclomethasone dipropionate represented a significant medication of the first therapeutic line in moderate isolated eosinophilic rhinitis, as well as in moderate bilateral eosinophilic nasal polyposis.

Download Full-text

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Monaldi Archives for Chest Disease ◽

10.4081/monaldi.2020.1397 ◽

2020 ◽

Vol 90 (3) ◽

Author(s):

Paolo Cameli ◽

Miriana D'Alessandro ◽

Laura Bergantini ◽

Elena Silvestri ◽

Arianna Romaldi ◽

...

Keyword(s):

Nasal Polyposis ◽

Potential Role ◽

Therapeutic Option ◽

Atopic Asthma ◽

Aspirin Exacerbated Respiratory Disease ◽

Nasal Symptoms ◽

Asthma Exacerbations ◽

Samter’S Triad ◽

One Year

Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the effectiveness of omalizumab in a multicentre group of patients with Samter’s triad. We retrospectively enrolled eight patients (5 females) with Samter’s triad who underwent at least one year of omalizumab therapy. Clinical data, functional parameters and questionnaires for asthma and nasal polyposis control were collected at baseline and follow-up. We observed a significant reduction of moderate-to-severe asthma exacerbations, together with an increase of FEV1 and a reduction of steroids intake. An improvement in asthma control and nasal symptoms was also reported. This multicenter study confirms the effectiveness of omalizumab in patients affected by Samter’s triad. Omalizumab may represent a potential therapeutic option for the management of this disease.

Download Full-text

Influence of nasal corticosteroid therapy duration on its efficiency at nasal polyposis

Russian Pulmonology ◽

10.18093/0869-0189-2005-0-2-107-112 ◽

2005 ◽

pp. 107-112

Author(s):

B. A. Chernyak ◽

E. V. Nosulya ◽

L. B. Sekretareva ◽

I. A. Kim

Keyword(s):

Nasal Polyposis ◽

Clinical Effect ◽

Normal Values ◽

Minimal Level ◽

Functional Parameters ◽

Nasal Symptoms ◽

Nasal Steroids ◽

Trial Phase

Efficacy of fluticasone propionate (FP) – Flixonase, GSK, in 76 patients with nasal polyposis (NP) was studied. After the first 3-month trial phase (FP 400 mcg / day), 46 patients (the 1 st group) have continued the 12-month treatment with FP 200 mcg / day, and 23 patients (the 2-nd group) have stopped the therapy with nasal steroids. Intensity of nasal symptoms using a 4-point scale, need for topical vasoconstrictors, rhinometric ventilation parameters (nasal inspiratory flow, NIF, nasal resistance, NR) and endoscopic symptoms were evaluated every 3 months. Trial results showed various shifts in clinical and functional parameters in the compared groups. The intensity of NP symptoms in the 1-st group decreased and reached the minimal level in 6 to 12 months, NIF rate reduced and NR decreased while reaching the normal values after 12 months of the FP therapy. The 2-nd patient group had a considerable worsening of the NP symptoms and in the functional parameters of the nasal breath within 3 months after FP cancellation. After 6 month follow up these indices did not differ essentially from those at the baseline condition. Thus, the early FP cancellation can cause instability of clinical effect and fast recurrence to the initial status. Long-term (for several months) therapy of NP with decrease in the FP dose in 3 months not only can keep the achieved results, but also allows to improve them considerably.

Download Full-text

Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial

BMC Endocrine Disorders ◽

10.1186/s12902-020-00670-w ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Fereidoun Azizi ◽

Hengameh Abdi ◽

Atieh Amouzegar

Keyword(s):

Low Dose ◽

Reference Range ◽

Antithyroid Drug ◽

Therapeutic Modality ◽

Thyroid Status ◽

Antithyroid Drug Therapy ◽

Daily Dose ◽

Prevention Of Relapse

Abstract Background Long-term antithyroid drug therapy has become one of the options for treatment of Graves’ hyperthyroidism. The aim of this study was to compare thyroid status in those who discontinued methimazole (MMI) treatment after 12.8 years with those who continued MMI as long as 24 years. Methods Fifty nine patients with Graves’ disease on long-term MMI for 14.2 ± 2.9 years were recruited; 32 patients (54%) decided to discontinue MMI and 27 (46%) preferred additional years of MMI treatment. All patients were followed for a mean of 6 additional years. Results Of 27 patients who continued MMI up to 24 years, suppressed serum thyrotropin (TSH) was not observed in any patient after the seventh year of treatment. Serum free thyroxine, triiodothyronine, TSH and TSH receptor antibody concentrations remained normal up to the length of the study. Mean daily dose of MMI to maintain TSH in the reference range decreased gradually and reached to 2.8 ± 1.7 mg by 24 years of MMI treatment. No adverse reaction related to MMI occured during additional years of therapy. In 32 patients who discontinued MMI, hyperthyroidism relapsed in 6 patients (19%), one left follow-up and 25 (78%) remained euthyroid during the study. Conclusions Long-term low dose MMI treatment may be a lifelong effective and safe therapeutic modality in patients with Graves’ hyperthyroidism for prevention of relapse, if studies from other centers confirm findings of this research. Trial registration IRCT201009224794N1, 2010-10-25. Retrospectively registered. https://www.irct.ir/trial/5143.

Download Full-text

AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.1362 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1132.3-1133

Author(s):

G. Jurado Quijano ◽

L. Fernández de la Fuente Bursón ◽

B. Hernández-Cruz ◽

P. Muñoz Reinoso ◽

V. Merino Bohóquez ◽

...

Keyword(s):

Survival Rates ◽

Categorical Variables ◽

Rank Test ◽

Published Data ◽

Disease Modifying Drugs ◽

Secondary Failure ◽

Daily Dose ◽

Student’S T ◽

Common Clinical Practice

Background:Rituximab (RTX) is a monoclonal antibody against the CD20 B cell antigen that has been used successfully in recent years for the treatment of rheumatoid arthritis (RA). It is an effective drug that reaches survival rates of 60% at 5 years of treatment as reflected in the British experience. However, survival in Spanish patients is unknown.Objectives:To study the survival of RTX treatment and the characteristics of patients with RA treated with the drug since its commercialization in Spain.Methods:Observational, retrospective and analytical study of a cohort of patients with RA treated with at least one dose of RTX. We reviewed the medical records of all patients with RA from January 2007 to June 2017. A total of 178 previous defined variables were collected, highlighting data about treatment (use of RTX, associated conventional synthetic disease modifying drugs [FAMEsc], doses of corticosteroids [GC] used) and activity indices. Descriptive statistics were performed (median and the 25th and 75th percentiles are shown). The comparative analysis was done with χ2 and U of Mann Whitney for categorical variables and paired sign rank test or Student’s t for continuous. Survival Kaplan Mayer curves were constructed. The study was carried out in accordance with the standards of our Clinical Research Ethics Committee.Results:A total of 54 patients were analyzed. 74% (n = 40) of them were women, the age was 61.2 years (51.0 - 67.4). 74% (n = 40) presented some type of relevant comorbidity. Its RA was FR + in 96% (n = 52) and ACCP + in 78% (n = 42) of the cases, with an evolution time of 9.3 years (3.5-19, 2), and with radiographic erosions in up to 63% (n = 34). At the time of the start of the RTX, 100% of the patients (n = 54) received some FAMEsc, and 33 (61%) were treated with prednisone; the daily dose of prednisone was 9 (6-12) mg. The baseline DAS28-VSG was 5 (4.1 - 6.0). The duration of the follow-up was 56.6 (29.3-92.1) months. Patients received a mean of 5 (1-6) cycles of RTX at a dose of 1000 mg on days 0 and 15 in most cases. The final DAS28-VSG was 2.6 (2.1 - 4.0), p = 0.00001 compared to baseline. The delta between baseline and final DAS was -2.36 (-0.55 - -3.1). At the end of the RTX treatment, the EULAR response rate was good in 64% (n = 25), reaching remission in 17 (31%) of the patients, and moderate response in 21% (n = 8) of them (Figure 1). Only 2 (4%) patients were treated with GCC at the end of the follow-up, p<0,00001 compared to baseline. The daily dose of PDN at the end of follow-up was 6 mg in a case and 12 mg in the other, p=00001 compared to baseline. At the end of the follow-up 24%of the patients (n = 13) changed or discontinued the drug: 9 changed due to secondary failure, 2 suspended due to adverse events, 1 due to death due to prior neoplastic process and 1 due to complete disease remission. Survival at 1, 2, 3, 4, 5, 6 and 7 years was 92%, 92%, 82% 78%, 75%, 75% and 65% respectively; with a mean survival rate of 90 months (Figure 1).Conclusion:The results of our analysis show that patients with RA undergoing RTX treatment have adequate control of disease activity and drug survival rates, like published data. RTX treatment allowed stopped GCC treatment in 31 cases (90%).References:[1]Oldroyd AGS, et al. Rheumatology (Oxford). 2018 Jun 1;57(6):1089-1096.Disclosure of Interests:Gonzalo Jurado Quijano: None declared, Lola Fernández de la Fuente Bursón: None declared, Blanca Hernández-Cruz Speakers bureau: Sociedad Española de Reumatología, Abbvie, Roche, Bristol, MSD, Lilly, Pfizer, Amgen, Sanofi, Consultant of: Abbvie, Lilly, Sanofi, STADA, UCB, Amgen, Grant/research support from: Fundación para la Investigación Sevilla, Junta de Andalucía, Fundación Andaluza de Reumatología, Paloma Muñoz Reinoso: None declared, Vicente Merino Bohóquez: None declared, José Javier Pérez Venegas: None declared

Download Full-text

Nasal symptoms increase the risk of snoring and snoring increases the risk of nasal symptoms. A longitudinal population study

Sleep And Breathing ◽

10.1007/s11325-020-02287-8 ◽

2021 ◽

Author(s):

Maria Värendh ◽

Christer Janson ◽

Caroline Bengtsson ◽

Johan Hellgren ◽

Mathias Holm ◽

...

Keyword(s):

Risk Factors ◽

Respiratory Health ◽

Smoking Status ◽

Northern Europe ◽

Nasal Breathing ◽

Nasal Symptoms ◽

Increased Risk ◽

Study Population ◽

Independent Risk Factors

Abstract Purpose Humans have a preference for nasal breathing during sleep. This 10-year prospective study aimed to determine if nasal symptoms can predict snoring and also if snoring can predict development of nasal symptoms. The hypothesis proposed is that nasal symptoms affect the risk of snoring 10 years later, whereas snoring does not increase the risk of developing nasal symptoms. Methods In the cohort study, Respiratory Health in Northern Europe (RHINE), a random population from Denmark, Estonia, Iceland, Norway, and Sweden, born between 1945 and 1973, was investigated by postal questionnaires in 1999–2001 (RHINE II, baseline) and in 2010–2012 (RHINE III, follow-up). The study population consisted of the participants who had answered questions on nasal symptoms such as nasal obstruction, discharge, and sneezing, and also snoring both at baseline and at follow-up (n = 10,112). Results Nasal symptoms were frequent, reported by 48% of the entire population at baseline, with snoring reported by 24%. Nasal symptoms at baseline increased the risk of snoring at follow-up (adj. OR 1.38; 95% CI 1.22–1.58) after adjusting for age, sex, BMI change between baseline and follow-up, and smoking status. Snoring at baseline was associated with an increased risk of developing nasal symptoms at follow-up (adj. OR 1.22; 95% CI 1.02–1.47). Conclusion Nasal symptoms are independent risk factors for development of snoring 10 years later, and surprisingly, snoring is a risk factor for the development of nasal symptoms.

Download Full-text

POS0338 STEROID-SPARING EFFECT OF ANAKINRA IN GIANT-CELL ARTERITIS: A CASE SERIES WITH CLINICAL, BIOLOGICAL AND ICONOGRAPHIC LONG-TERM ASSESSMENTS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.1623 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 397.1-397

Author(s):

S. Deshayes ◽

K. Ly ◽

V. Rieu ◽

G. Maigné ◽

N. M. Silva ◽

...

Keyword(s):

Giant Cell Arteritis ◽

Giant Cell ◽

Interleukin 1 ◽

Oral Prednisone ◽

Large Vessel ◽

Daily Dose ◽

Sparing Effect ◽

Steroid Sparing

Background:The treatment of giant cell arteritis (GCA) relies on corticosteroids but is burdened by a high rate of relapses and adverse effects. Anti-interleukin-6 treatments show a clear benefit with a significant steroid-sparing effect, but late relapses occur after treatment discontinuation. In addition to interleukin-6, interleukin-1 also appears to play a significant role in GCA pathophysiology.Objectives:We report herein the efficacy of anakinra, an interleukin-1 receptor antagonist, in 6 GCA patients exhibiting corticosteroid dependence or resistance, specifically analyzing the outcome of aortitis in 4 of them, and including the long-term follow-up of 2 previously described patients (1).Methods:This retrospective study analyzed the cases of all GCA patients treated with anakinra from the French Study Group for Large Vessel Vasculitis.Patients had to satisfy the following two criteria to be enrolled in this retrospective study. First, their diagnosis of GCA should be based on the fulfillment of at least 3 criteria of the American College of Rheumatology (ACR) for GCA or on the satisfaction of 2 of these criteria along with the demonstration of LVI on imaging. Second, patients should have received anakinra because of corticosteroid dependence or resistance.Corticosteroid dependence was defined as ≥2 relapses or the combination of 2 of the following criteria: a daily dose of oral prednisone >20 mg/day (or 0.3 mg/kg) at 6 months; a daily dose of oral prednisone >10 mg/day (or 0.2 mg/kg) at 12 months; and/or a treatment maintained >24 months because of a relapsing disease course. Corticosteroid resistance was defined as persistent increased inflammatory parameters at month 3 despite a steroid dosage over 0.5 mg/kg.Results:After a median duration of anakinra therapy of 19 [18–32] months, all 6 patients exhibited complete clinical and biological remission. Among the 4 patients with large-vessel involvement, 2 had a disappearance of aortitis under anakinra, and 2 showed a decrease in vascular uptake. After a median follow-up of 56 [48–63] months, corticosteroids were discontinued in 4 patients, and corticosteroid dosage could be decreased to 5 mg/day in 2 patients. One patient relapsed 13 months after anakinra introduction in the context of increasing the daily anakinra injection interval to every 48 hours. Three patients experienced transient injection-site reactions, and 1 patient had pneumonia.Figure 1.Steroid dosages before and after the introduction of anakinra in 6 patients with giant-cell arteritis and corticosteroid dependence or resistance. The black arrow indicates the time of anakinra introduction.Conclusion:In this short series, anakinra appears to be an efficient and safe steroid-sparing agent in refractory GCA, with a possible beneficial effect on large-vessel involvement.References:[1]Ly K-H, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais A-L. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine 2014;81:76–8.Disclosure of Interests:Samuel Deshayes: None declared, Kim LY: None declared, Virginie Rieu: None declared, Gwénola Maigné: None declared, Nicolas Martin Silva: None declared, Alain Manrique: None declared, Jacques Monteil: None declared, Hubert de Boysson Speakers bureau: Roche-Chugai, Grant/research support from: Roche-Chugai, Achille Aouba Grant/research support from: SOBI

Download Full-text

Alpha-Interferon (Wellferon) as an Adjunct to Standard Surgical Therapy in the Management of Recurrent Respiratory Papillomatosis

Annals of Otology Rhinology & Laryngology ◽

10.1177/000348948809700409 ◽

1988 ◽

Vol 97 (4) ◽

pp. 376-380 ◽

Cited By ~ 14

Author(s):

Bruce N. Benjamin ◽

Henley Harrison ◽

Paul A. Gatenby ◽

Kaye Cameron ◽

Robert Kitchen ◽

...

Keyword(s):

Complete Remission ◽

Crossover Study ◽

Total Dose ◽

Laser Therapy ◽

Partial Remission ◽

Recurrent Respiratory Papillomatosis ◽

Alpha Interferon ◽

High Dose ◽

Daily Dose

Ten patients received lymphoblastoid alpha-interferon (Wellferon) in a crossover study so that Wellferon and standard microsurgical laryngeal laser therapy could be compared to laser therapy alone. Wellferon was administered initially at an intravenous high dose of 15 megaunits/m2 for 5 days followed by a daily dose of 2 megaunits/m2 subcutaneously for 6 months. Dosage was adjusted according to predefined toxicity. One patient was withdrawn from the study. Of the others, all but one received over 75 % of the planned total dose. At follow-up of the nine assessable patients, complete remission was achieved in two of them, partial remission in four, and no response in the remainder. The two complete remissions were sustained for 2 years, but the four partial remissions were not sustained. Thus, a role for alpha-interferon in the kind of regimen used here remains to be established.

Download Full-text

S103 – Mometasone Is Effective With or Without Oral Antihistamines

Otolaryngology ◽

10.1016/j.otohns.2008.05.276 ◽

2008 ◽

Vol 139 (2_suppl) ◽

pp. P112-P112

Author(s):

Joao Antonio Marta Pimentel

Keyword(s):

Nasal Discharge ◽

Daily Routine ◽

Efficacy And Safety ◽

Concomitant Therapy ◽

Open Label ◽

Daily Routines ◽

Oral Antihistamine ◽

Intranasal Corticosteroids ◽

Nasal Symptoms ◽

Symptom Scores

Objectives Clinical trials have demonstrated the efficacy of monotherapy with intranasal corticosteroids (INSs) for symptoms of allergic rhinitis (AR). ARIA guidelines suggest adding oral antihistamines to INS monotherapy when severe symptoms do not improve. An open-label multicenter study assessed efficacy and safety of mometasone furoate nasal spray (MFNS) alone or combined with an oral antihistamine in subjects with AR. Methods Subjects received MFNS 200 mcg QD for 56 days, with an oral antihistamine added at Day 28 or later if baseline symptoms (sneezing, nasal discharge/obstruction, tiredness, irritability) had not improved. Subjects rated individual symptom scores, daily routine and sleep limitations, and product attributes on Days 1, 28, and 56 on a scale of 0 to 10, and completed a compliance questionnaire on Day 56. Results Mean scores for AR symptoms and limitations on sleep and daily routines significantly improved from baseline to Day 28 and from Day 28 to 56 (P less than 0.001 for all). At Days 28 and 56, 47/60 and 45/56 subjects, respectively, were receiving MFNS monotherapy, and 13 required a concomitant oral antihistamine at Day 28 or later. By Day 56, symptom severity improved in 92% of subjects receiving concomitant therapy. At study end, 88% of subjects reported compliance with QD MFNS. Average product attribute scores ranged from 7.2 to 8.4. No severe adverse events were reported. Conclusions MFNS 200 mcg QD, alone or combined with an oral antihistamine, was safe and effective against AR nasal symptoms and limitations of sleep and daily activities.

Download Full-text

Acute proptosis secondary to bilateral pansinus mucopyocele with orbital compartment syndrome: a rare presentation, its management and outcome

BMJ Case Reports ◽

10.1136/bcr-2021-241972 ◽

2021 ◽

Vol 14 (7) ◽

pp. e241972

Author(s):

Khushboo Chauhan ◽

Tanya Sharma ◽

Bhavana Sharma ◽

Samendra Karkhur

Keyword(s):

Compartment Syndrome ◽

Nasal Polyposis ◽

Signs And Symptoms ◽

Sinus Surgery ◽

Rare Presentation ◽

Diagnostic Dilemma ◽

Guided Exploration ◽

Rapid Relief ◽

Maxillary Sinuses

A 37-year-old Indian female presented with forward protrusion of left eye for one week, associated with progressive diminution of vision. The patient had undergone sinus surgery for nasal polyposis a year ago. On examination, there was severe proptosis and limitation of extraocular movements in all gazes. CT-scan revealed a heterogeneous expansile mass, arising from left fronto-ethmoidal sinus, infiltrating left orbit. MRI showed T2-hyperintense, peripherally enhancing areas in bilateral nasal cavity (right >left), bilateral ethmoidal sinuses and frontal, sphenoidal and maxillary sinuses. Otorhinolaryngology consultation was sought and in view of vision threatening proptosis — with likely orbital compartment syndrome — emergent endoscopic guided exploration and orbital decompression was undertaken. Rapid relief of signs and symptoms was achieved, with normal vision, extraocular movements and resolution of proptosis. Cytology and microbiology ruled out infectious or malignant aetiology and helped in resolving a diagnostic dilemma. Histopathology confirmed the diagnosis of mucopyocele and follow-up period was uneventful.

Download Full-text

546 Management of Pediatric Pavement Burns

Journal of Burn Care & Research ◽

10.1093/jbcr/irab032.196 ◽

2021 ◽

Vol 42 (Supplement_1) ◽

pp. S121-S122

Author(s):

Syed F Saquib ◽

Paul J Chestovich ◽

Joseph T Carroll ◽

Carmen E Flores

Keyword(s):

Ambient Temperature ◽

Average Length ◽

Topical Therapy ◽

Total Body Surface Area ◽

High Ambient Temperature ◽

Unknown Etiology ◽

Oral Antibiotic ◽

Superficial Infection ◽

Plantar Aspect

Abstract Introduction Pavement burns are common in a dry high heat climate. This study reviews the etiology, management and outcome of pavement burns in children. Methods All patients age < 18 who suffered contact burns from hot pavement from Jan 1, 2014 to Dec 31, 2019 were reviewed. A total of 45 patient charts met inclusion criteria. High ambient temperature on each date, and zip code of each injury was extracted from Weather Underground (www.wunderground.com) Results In this study, 45 patients met criteria and were reviewed, of whom 27 patients (60%) were male. Average age was 3.29 years (SD 0.69), made up two discrete age groups: age under 3 (n= 40, 89%) and 14+ (n=5, 11%). 38 patients (84%) had no known medical history. All had 2nd degree burns and one patient (2%) had third degree burns. Mean total body surface area (TBSA) was 2.5% (SD 1.4%, range 0.75% to 5.5%). Burn etiology included 31 patients (69%) walking barefoot on pavement, 6 (13%) falling onto pavement, and other/unknown etiology for the remaining 8 patients (18%). 30 patients (67%) had injuries on the plantar aspect of bilateral feet, 2 (4%) to bilateral palms of hands, 4 (9%) to other parts of upper extremities and 10 (22%) to other parts of lower extremities. Thirty-four (34) patients (76%) were managed without any hospitalization. Those that were hospitalized had an average length of stay (LOS) of 2.72 days (range 1–9 days). All burns were managed non-operatively with topical therapy alone. 35 patients (78%) were managed initially with Silvadene, and 6 (13%) with bacitracin. Aquacel was utilized in 10 patients at a follow-up visit (22%). Three patients (6.7%) were treated with collagenase enzyme therapy. One patient developed a superficial infection requiring oral antibiotic therapy. There were no mortalities in this group. The high ambient temperature on date and location of each injury was 101 F (SD 1.10 F, range 73F-111F). Of the thirty that continued to follow up in clinic, the average time to the burn being 95% healed was 10.50 days (SD 8.97 days, range 2–40 days). Conclusions Pavement burns in children are partial thickness and are safely managed with topical therapy alone, with good outcomes. Patients age 3 and under are a vulnerable population and therefore at particular risk of injury.

Download Full-text